S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BrainsWay Ltd. stock logo
BWAY
BrainsWay
$5.05
-1.2%
$5.90
$1.38
$7.61
$84.03M1.2124,863 shs16,659 shs
DarioHealth Corp. stock logo
DRIO
DarioHealth
$1.21
+3.4%
$1.71
$0.68
$4.58
$35.62M1.66137,691 shs59,906 shs
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
$0.02
$0.02
$0.00
$0.03
$27.43M0.99331,291 shs592,735 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$3.96
-2.0%
$3.88
$1.03
$5.07
$118.72M2.44192,605 shs23,740 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-1.17%-6.48%-16.67%-19.07%+198.82%
DarioHealth Corp. stock logo
DRIO
DarioHealth
+2.54%-7.63%-19.33%-51.01%-64.41%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
+20.50%+26.18%+20.50%+2.12%+13.68%
Neuronetics, Inc. stock logo
STIM
Neuronetics
-1.98%-8.55%+4.49%+23.75%+91.30%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BrainsWay Ltd. stock logo
BWAY
BrainsWay
2.4881 of 5 stars
3.35.00.00.02.50.80.6
DarioHealth Corp. stock logo
DRIO
DarioHealth
1.2162 of 5 stars
3.52.00.00.00.00.81.3
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.7876 of 5 stars
3.33.00.00.01.91.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BrainsWay Ltd. stock logo
BWAY
BrainsWay
2.67
Moderate Buy$7.0038.61% Upside
DarioHealth Corp. stock logo
DRIO
DarioHealth
3.00
Buy$5.37343.53% Upside
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.50
Moderate Buy$8.00102.02% Upside

Current Analyst Ratings

Latest STIM, DRIO, BWAY, and SNWV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
DarioHealth Corp. stock logo
DRIO
DarioHealth
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
3/26/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/11/2024
BrainsWay Ltd. stock logo
BWAY
BrainsWay
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
3/6/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BrainsWay Ltd. stock logo
BWAY
BrainsWay
$31.78M2.64N/AN/A$2.50 per share2.02
DarioHealth Corp. stock logo
DRIO
DarioHealth
$20.35M1.75N/AN/A$2.14 per share0.57
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
$20.40M1.34N/AN/A($0.04) per share-0.60
Neuronetics, Inc. stock logo
STIM
Neuronetics
$71.35M1.66N/AN/A$1.18 per share3.36

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-$4.20M-$0.13N/A63.13N/A-13.20%-10.05%-6.88%5/15/2024 (Estimated)
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$59.43M-$1.03N/AN/AN/A-165.96%-48.84%-31.56%5/9/2024 (Estimated)
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
-$25.81M-$0.03N/AN/A-126.52%N/A-32.63%5/10/2024 (Estimated)
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$30.19M-$1.07N/AN/AN/A-42.31%-72.76%-29.25%5/14/2024 (Estimated)

Latest STIM, DRIO, BWAY, and SNWV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/A$0.03+$0.03$0.03N/A$6.99 million
3/6/202412/31/2023
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-$0.03-$0.01+$0.02N/A$8.40 million$9.03 million    
3/5/202412/31/2023
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BrainsWay Ltd. stock logo
BWAY
BrainsWay
N/AN/AN/AN/AN/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
N/AN/AN/AN/AN/A
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BrainsWay Ltd. stock logo
BWAY
BrainsWay
N/A
5.68
5.30
DarioHealth Corp. stock logo
DRIO
DarioHealth
0.42
3.79
3.38
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
N/A
0.15
0.11
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.73
4.73
4.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BrainsWay Ltd. stock logo
BWAY
BrainsWay
30.11%
DarioHealth Corp. stock logo
DRIO
DarioHealth
33.39%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
42.53%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%

Insider Ownership

CompanyInsider Ownership
BrainsWay Ltd. stock logo
BWAY
BrainsWay
19.00%
DarioHealth Corp. stock logo
DRIO
DarioHealth
10.10%
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
16.40%
Neuronetics, Inc. stock logo
STIM
Neuronetics
5.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BrainsWay Ltd. stock logo
BWAY
BrainsWay
13416.64 million13.48 millionNot Optionable
DarioHealth Corp. stock logo
DRIO
DarioHealth
27629.44 million26.47 millionOptionable
SANUWAVE Health, Inc. stock logo
SNWV
SANUWAVE Health
311.14 billion953.51 millionNot Optionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
20329.98 million28.42 millionOptionable

STIM, DRIO, BWAY, and SNWV Headlines

SourceHeadline
Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%
marketbeat.com - April 12 at 3:58 PM
New Study Offers Hope for Depression Patients Undergoing TMS TherapyNew Study Offers Hope for Depression Patients Undergoing TMS Therapy
msn.com - April 12 at 1:57 AM
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalNew Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
globenewswire.com - April 10 at 8:31 AM
Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)
marketbeat.com - April 6 at 7:36 PM
Neuronetics Stock (NASDAQ:STIM), Quotes and News SummaryNeuronetics Stock (NASDAQ:STIM), Quotes and News Summary
benzinga.com - April 5 at 5:38 AM
Neuronetics (STIM) FDA-Cleared NeuroStar to Aid in DepressionNeuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
zacks.com - April 1 at 11:56 AM
Neuronetics Bolsters Talent Pool with Strategic Stock Incentives for New HiresNeuronetics Bolsters Talent Pool with Strategic Stock Incentives for New Hires
msn.com - April 1 at 1:05 AM
Neurostar cleared for use in adolescent depressionNeurostar cleared for use in adolescent depression
bioworld.com - March 29 at 12:15 AM
FDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatmentFDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatment
medicaldialogues.in - March 29 at 12:15 AM
FDA Clears NeuroStars TMS Therapy for Adolescents with Major Depressive DisorderFDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder
msn.com - March 29 at 12:15 AM
Neuronetics, Inc. (NASDAQ:STIM) Short Interest UpdateNeuronetics, Inc. (NASDAQ:STIM) Short Interest Update
marketbeat.com - March 28 at 11:57 AM
Neuronetics wins FDA clearance for device to treat adolescents with depressionNeuronetics wins FDA clearance for device to treat adolescents with depression
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - March 27 at 4:30 PM
Buy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD MarketBuy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD Market
markets.businessinsider.com - March 27 at 6:41 AM
Neuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depressionNeuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depression
fiercebiotech.com - March 27 at 6:41 AM
Neuronetics (STIM) "Market Perform" Rating Reiterated at William BlairNeuronetics' (STIM) "Market Perform" Rating Reiterated at William Blair
marketbeat.com - March 26 at 3:29 PM
TMS Device NeuroStar Cleared as Add-On Treatment for Adolescent DepressionTMS Device NeuroStar Cleared as Add-On Treatment for Adolescent Depression
empr.com - March 26 at 3:49 AM
Neuronetics’s NeuroStar wins FDA clearance for adolescents with depressionNeuronetics’s NeuroStar wins FDA clearance for adolescents with depression
msn.com - March 25 at 10:48 PM
Neuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionNeuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
finanznachrichten.de - March 25 at 12:07 PM
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21
marketwatch.com - March 25 at 12:07 PM
Neuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New IndicationNeuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New Indication
markets.businessinsider.com - March 25 at 12:07 PM
FDA clears Neuronetics’ neurostim for adolescents with depressionFDA clears Neuronetics’ neurostim for adolescents with depression
massdevice.com - March 25 at 12:07 PM
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionNeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
globenewswire.com - March 25 at 8:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

BrainsWay logo

BrainsWay

NASDAQ:BWAY
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, the Asia Pacific, Europe, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
DarioHealth logo

DarioHealth

NASDAQ:DRIO
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
SANUWAVE Health logo

SANUWAVE Health

OTCMKTS:SNWV
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's pulsed acoustic cellular expression systems, including dermaPACE system for treating diabetic foot ulcers and other chronic wounds; orthoPACE system for treating tendinopathies and acute and nonunion fractures; and Profile is used to provide therapeutic treatment of musculoskeletal conditions. Its portfolio of wound treatment solutions provides patients with a noninvasive technology that boosts the body's normal healing and tissue regeneration processes. In addition, the company offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. SANUWAVE Health, Inc. was founded in 2004 and is headquartered in Eden Prairie, Minnesota.
Neuronetics logo

Neuronetics

NASDAQ:STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.